SABS
Income statement / Annual
Last year (2023), SAB Biotherapeutics, Inc.'s total revenue was $2.24 M,
a decrease of 90.63% from the previous year.
In 2023, SAB Biotherapeutics, Inc.'s net income was -$42.19 M.
See SAB Biotherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$2.24 M
|
$23.90 M
|
$60.88 M
|
$55.24 M
|
$3.44 M
|
| Cost of Revenue |
$3.75 M |
$3.29 M |
$1.65 M |
$0.00 |
$0.00 |
| Gross Profit |
-$1.51 M |
$20.61 M |
$59.22 M |
$55.24 M |
$3.44 M |
| Gross Profit Ratio |
-0.67 |
0.86 |
0.97 |
1 |
1 |
| Research and Development
Expenses |
$16.52 M
|
$36.44 M
|
$57.18 M
|
$27.91 M
|
$8.02 M
|
| General & Administrative
Expenses |
$23.80 M
|
$16.38 M
|
$17.09 M
|
$6.77 M
|
$4.10 M
|
| Selling & Marketing
Expenses |
-$3.75 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$20.05 M
|
$16.38 M
|
$17.09 M
|
$6.77 M
|
$4.10 M
|
| Other Expenses |
$0.00 |
-$23.90 M |
-$60.88 M |
$3,996.00 |
$2,594.00 |
| Operating Expenses |
$40.31 M |
$28.92 M |
$13.39 M |
$34.68 M |
$12.12 M |
| Cost And Expenses |
$40.31 M |
$28.92 M |
$13.39 M |
$34.68 M |
$12.12 M |
| Interest Income |
$584,966.00 |
$71,072.00 |
$23,115.00 |
$26,131.00 |
$113,133.00 |
| Interest Expense |
$315,284.00 |
$301,584.00 |
$294,459.00 |
$469,151.00 |
$428,476.00 |
| Depreciation &
Amortization |
$3.75 M
|
$3.29 M
|
$1.65 M
|
$548,178.00
|
$323,407.00
|
| EBITDA |
-$38.13 M
|
-$15.12 M
|
-$15.20 M
|
$21.14 M
|
-$8.23 M
|
| EBITDA Ratio |
-17.03 |
-1.14 |
-0.19 |
0.38 |
-2.39 |
| Operating Income Ratio
|
-17.01
|
-1.21
|
-0.22
|
0.37
|
-2.52
|
| Total Other
Income/Expenses Net |
-$4.12 M
|
$10.20 M
|
-$3.75 M
|
-$439,024.00
|
-$312,749.00
|
| Income Before Tax |
-$42.19 M |
-$18.72 M |
-$17.14 M |
$20.12 M |
-$8.99 M |
| Income Before Tax Ratio
|
-18.85
|
-0.78
|
-0.28
|
0.36
|
-2.61
|
| Income Tax Expense |
$0.00 |
$25,629.00 |
$299,947.00 |
$473,147.00 |
$431,070.00 |
| Net Income |
-$42.19 M |
-$18.74 M |
-$17.44 M |
$20.12 M |
-$9.42 M |
| Net Income Ratio |
-18.85 |
-0.78 |
-0.29 |
0.36 |
-2.74 |
| EPS |
-7.64 |
-4.31 |
-6.38 |
7.92 |
-0.22 |
| EPS Diluted |
-7.64 |
-4.31 |
-6.38 |
7.45 |
-0.22 |
| Weighted Average Shares
Out |
$5.52 M
|
$4.35 M
|
$2.73 M
|
$2.54 M
|
$43.47 M
|
| Weighted Average Shares
Out Diluted |
$5.52 M
|
$4.35 M
|
$2.73 M
|
$2.70 M
|
$43.47 M
|
| Link |
|
|
|
|
|
